Grant of Interim Extension of the Term of U.S. Patent No. 8,858,612; Reducer®, 17315 [2020-06447]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 60 / Friday, March 27, 2020 / Notices
for annual determination, thus
providing flexibility in responding to
salmon management concerns in any
given year.
Notice of interim Patent term
extension.
ACTION:
II. Method of Collection
Notifications are made by at-sea radio
or cellular phone transmissions.
III. Data
OMB Control Number: 0648–0433.
Form Number(s): None.
Type of Review: Regular submission
(extension of a currently approved
collection).
Affected Public: Business or other forprofit organizations.
Estimated Number of Respondents:
40.
Estimated Time per Response: 15
minutes.
Estimated Total Annual Burden
Hours: 10 hours.
Estimated Total Annual Cost to
Public: $0 in recordkeeping/reporting
costs.
IV. Request for Comments
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden
(including hours and cost) of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology.
Comments submitted in response to
this notice will be summarized and/or
included in the request for OMB
approval of this information collection;
they also will become a matter of public
record.
Dated: March 24, 2020.
Sheleen Dumas,
Department PRA Clearance Officer, Office of
the Chief Information Officer, Commerce
Department.
[FR Doc. 2020–06402 Filed 3–26–20; 8:45 am]
BILLING CODE 3510–22–P
khammond on DSKJM1Z7X2PROD with NOTICES
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO–P–2020–0019]
Grant of Interim Extension of the Term
of U.S. Patent No. 8,858,612; Reducer®
United States Patent and
Trademark Office, Commerce.
AGENCY:
VerDate Sep<11>2014
16:28 Mar 26, 2020
Jkt 250001
The United States Patent and
Trademark Office has issued an order
granting interim extension for a oneyear interim extension of the term of
U.S. Patent No. 8,858,612.
FOR FURTHER INFORMATION CONTACT: Ali
Salimi by telephone at (571) 272–0909;
by mail marked to his attention and
addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to his attention at
(571) 273–0909; or by email to
ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On March 11, 2020, Neovasc Medical
Ltd., the patent owner of record, timely
filed an application under 35 U.S.C.
156(d)(5) for an interim extension of the
term of U.S. Patent No. 8,858,612. The
patent claims method of use of catheter
delivered implantable device, Reducer®.
The application for patent term
extension indicates that a Premarket
Approval Application (PMA) P190035
was submitted to the Food and Drug
Administration (FDA) on December 31,
2019.
Review of the patent term extension
application indicates that, except for
permission to market or use the product
commercially, the subject patent would
be eligible for an extension of the patent
term under 35 U.S.C. 156, and that the
patent should be extended for one year
as required by 35 U.S.C. 156(d)(5)(B).
Because the regulatory review period
will continue beyond the original
expiration date of the patent, March 27,
2020, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
8,858,612 is granted for a period of one
year from the original expiration date of
the patent.
SUMMARY:
Robert Bahr,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
[FR Doc. 2020–06447 Filed 3–26–20; 8:45 am]
BILLING CODE 3510–16–P
PO 00000
Frm 00012
Fmt 4703
Sfmt 4703
17315
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2020–0020]
Grant of Interim Extension of the Term
of U.S. Patent No. 6,953,476; Reducer®
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting interim extension under 35
U.S.C. 156(d)(5) for a one-year interim
extension of the term of U.S. Patent No.
6,953,476.
FOR FURTHER INFORMATION CONTACT: Ali
Salimi by telephone at (571) 272–0909;
by mail marked to his attention and
addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to his attention at
(571) 273–0909; or by email to
ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On March 11, 2020, Neovasc Medical
Ltd., the patent owner of record, timely
filed an application under 35 U.S.C.
156(d)(5) for an interim extension of the
term of U.S. Patent No. 6,953,476. The
patent claims a catheter delivered
implantable device, Reducer®. The
application for patent term extension
indicates that a Premarket Approval
Application (PMA) P190035 was
submitted to the Food and Drug
Administration (FDA) on December 31,
2019.
Review of the patent term extension
application indicates that, except for
permission to market or use the product
commercially, the subject patent would
be eligible for an extension of the patent
term under 35 U.S.C. 156, and that the
patent should be extended for one year
as required by 35 U.S.C. 156(d)(5)(B).
Because the regulatory review period
will continue beyond the original
expiration date of the patent, March 27,
2020, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
SUMMARY:
E:\FR\FM\27MRN1.SGM
27MRN1
]]>Agencies
[Federal Register Volume 85, Number 60 (Friday, March 27, 2020)]
[Notices]
[Page 17315]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06447]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO-P-2020-0019]
Grant of Interim Extension of the Term of U.S. Patent No.
8,858,612; Reducer[supreg]
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of interim Patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension for a one-year interim extension of
the term of U.S. Patent No. 8,858,612.
FOR FURTHER INFORMATION CONTACT: Ali Salimi by telephone at (571) 272-
0909; by mail marked to his attention and addressed to the Commissioner
for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA
22313-1450; by fax marked to his attention at (571) 273-0909; or by
email to [email protected].
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On March 11, 2020, Neovasc Medical Ltd., the patent owner of
record, timely filed an application under 35 U.S.C. 156(d)(5) for an
interim extension of the term of U.S. Patent No. 8,858,612. The patent
claims method of use of catheter delivered implantable device,
Reducer[supreg]. The application for patent term extension indicates
that a Premarket Approval Application (PMA) P190035 was submitted to
the Food and Drug Administration (FDA) on December 31, 2019.
Review of the patent term extension application indicates that,
except for permission to market or use the product commercially, the
subject patent would be eligible for an extension of the patent term
under 35 U.S.C. 156, and that the patent should be extended for one
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory
review period will continue beyond the original expiration date of the
patent, March 27, 2020, interim extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 8,858,612 is granted for a period of one year from the
original expiration date of the patent.
Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent
and Trademark Office.
[FR Doc. 2020-06447 Filed 3-26-20; 8:45 am]
BILLING CODE 3510-16-P
